Zimbabwe has turned down a substantial US healthcare agreement valued at 367 million US dollars (£272m) spanning five years due to the United States' request for sensitive data.
This rejection came to light after a official document from December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson has since clarified that the US was requesting health data for scientific study and commercial gain while was not willing to share the benefits from any future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued talks to secure a deal suitable to both sides so the nation's critical HIV treatment initiative can proceed.
Broader Context
This rejection comes after a comparable case in Kenya, where a high court halted a related health funding agreement following concerns were raised about the security of Kenyans' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
According to reports, 16 nations in Africa have so far signed similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving HIV treatment through US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent assurance of access to any medical innovations – like new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our nation would supply the basic resources for medical research with no certainty that the end products would be available to our population should a future health crisis emerge."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of bilateral deals were undermining structures already set up via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This framework is intended to ensure that when a nation contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how future co-operation could be structured in a way that honours the independence and interests of both nations."
Health Experts Response
A leading public health body stated it acknowledged the official position, but recommended that talks need to persist considering much of the nation's Aids initiatives depended on external financing.
"Where specific concerns exist, including those relating to information security or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," the group said.
The situation underscores the continuing challenges between accepting crucial international aid and protecting national sovereignty in an ever more interconnected world.